Vomiting

01/01/1999 - "However, there was a significant reduction in emesis management costs for patients treated after versus before the availability of ondansetron: for patients treated in the last third versus first third of the study period, there was a decrease in cost per patient per month of treatment of $374 (95% confidence interval, $243 to $505). "
03/01/1996 - "The need for antiemetic rescue therapy (ondansetron 0.15 mg/kg intravenously after three episodes of emesis prior to discharge) was significantly greater in children who received placebo compared with the ondansetron 0.15 mg/kg study group (13% vs 0%, P < 0.05). "
11/01/2012 - "In conclusion, the administration of oral ondansetron to children with vomiting in the emergency department is clinically effective and results in significant economic savings."
12/01/2001 - "The incidence of vomiting was significantly greater after infusion of placebo than after either low-dose or high-dose ondansetron. "
12/01/1997 - "All doses of ondansetron 0.05 mg/kg, 0.1 mg/kg, and 0.15 mg/kg were significantly more effective than placebo in reducing the incidence of emesis prior to, following discharge, and during the first 24 postoperative hours (p < 0.001). "

02/01/2000 - "All three agents were highly effective against cisplatin-induced acute and late vomiting and the results were statistically significant. "
01/01/1992 - "Most patients (64%) experienced emesis if C[4h] was < 20 ng/ml, whereas emesis did not occur in any patient with C[4h] > 80 ng/ml. Among patients receiving very high dosages of cisplatin (> 95 mg/m2), comparable levels of systemic exposure were not totally effective in preventing emesis. "
07/01/2002 - "As for emesis induced by cisplatin, an optimal antiemetic schedule is effective in 70-90% of cases of acute emesis, in 60% of cases of delayed emesis, whereas acute emesis induced by moderately emetogenic agents can be prevented in over 90% of cases. "
05/01/1983 - "Good results have been achieved in patients not previously treated with cisplatin, but further studies are needed to determine its level of efficacy in patients who have experienced severe vomiting during earlier courses of cytotoxic therapy. "
07/01/1988 - "These results indicate that high-dose MCP plus DPH are effective in preventing cisplatin-induced vomiting. "

04/01/2008 - "A significant reduction in vomiting from 27% to 11% was achieved following the introduction of routine use of intravenous dexamethasone during surgery. "
04/01/2003 - "Compared with placebo, dexamethasone significantly decreased the incidence of early and late vomiting (P < 0.05, P < 0.001 respectively). "
02/01/1995 - "Addition of dexamethasone significantly improved prevention of both acute and delayed emesis. "
01/01/1998 - "Six patients in group D and 19 in group S experienced vomiting at least once within the 24-h postoperative period; dexamethasone was effective in reducing the overall incidence of vomiting from 63.3% to 20.0% (P < 0.01). "
10/01/2000 - "Dexamethasone is clearly effective in protecting from emesis both in the acute and delayed phases, with emesis avoided in one patient out of six treated. "

04/01/2015 - "Recent studies show that, especially in the therapy of opioid-triggered vomiting, metoclopramide is not significantly effective when compared to placebo. "
11/01/1989 - "There was a significant reduction in the number of episodes of vomiting during the first 24 h in patients receiving the metoclopramide combination (P = 0.0001). "
11/01/1984 - "Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting."
01/01/1985 - "The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis. "
08/01/2011 - "All three studies were included in the final meta-analysis that demonstrated an overall result of no difference between metoclopramide and placebo for the primary outcome of vomiting (odds ratios 0.72; 95% confidence intervals 0.11-4.58). "

08/01/2012 - "The efficacy of granisetron was measured on each day using the complete regression(no vomiting and no rescue medication; CR)rate. "
09/01/1997 - "The percentage of emesis-free patients was significantly greater in the 5- to 20-microg/kg granisetron groups than in the control and 2-microg/kg granisetron groups (18%, 23%, 68%, 78%, and 75% of patients receiving saline or granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg, respectively). "
08/01/2003 - "Additionally, incremental doses of granisetron (up to 9 mg) have been shown to be effective and well tolerated in patients with refractory emesis. "
01/01/1994 - "The efficacy of Granisetron, a new and selective 5HT3-receptor-antagonist in the treatment of cytostatic induced emesis, was tested in the department of gynaecology and obstetrics of the University of Essen on 77 patients. "
11/15/1995 - "However, the addition of corticosteroid to orally administered granisetron improved the control of delayed emesis. "

02/01/2004 - "Two pivotal phase III trials enrolling a total of 1099 patients showed that the complete control of emesis improved by 20% in patients receiving aprepitant as compared with standard therapy, with the most impressive differences being in delayed emesis. "
07/01/2011 - "Vomiting was dramatically reduced by the concomitant administration of aprepitant. "
01/01/2013 - "Patients aged 65 and over have a significantly greater chance of experiencing a complete response (no vomiting or use of rescue therapy) to antiemetic treatment when aprepitant is included in the antiemetic regimen (Risk Ratio 1.25, 95% Confidence Interval 1.11 to 1.40, p=0.0002) than when it is not. "
06/01/2011 - "Aprepitant markedly improved control of emesis in patients with one or more risk factors. "
04/01/2010 - "The aprepitant regimen provided superior efficacy in the treatment of CINV in a broad range of patients receiving MEC (non-AC or AC) in both no vomiting and complete response endpoints. "

07/01/2012 - "Clinical efficacy of anti-emetics is highly correlated with efficacy in the ferret emesis model, suggesting rolapitant is a viable clinical candidate for this indication."
08/01/2008 - "Experimental data provide evidence for efficacy against a wide range of peripheral and central emetic stimuli and clinical trials confirm that neurokinin-1 antagonists have significantly higher efficacy against vomiting than all other antiemetics, with relative risk reductions of over 50%. "
05/01/2003 - "Available data indicates that the 5-HT3-receptor antagonists are at least as good as conventional antiemetics in controlling delayed-onset emesis, and that their efficacy in this setting may be improved by the addition of a corticosteroid. "
03/01/1987 - "Combination anti-emesis has further improved control rates and new schedules of currently available anti-emetics are now proving their worth. "
06/01/2007 - "These findings further suggest that the least shrew can be utilized as a versatile and inexpensive small animal model to rapidly screen the efficacy of investigational antiemetics for the prevention of radiation-induced emesis."

04/01/1996 - "Furthermore, based on our improved knowledge of the role of 5-HT in emesis and gastrointestinal motility, the therapeutic potential of potent mixed 5-HT4 agonists--5-HT3 antagonists in the control of cytotoxic-drug-induced emesis and associated gut motor disturbances will be discussed. "
01/01/2008 - "Although the development of serotonin receptor antagonists has greatly improved the control of acute emesis, delayed CINV remains a significant clinical issue. "
06/01/2003 - "Combination therapy with a 5-hydroxytryptamine (5-HT3) receptor antagonist and a steroid preparation is effective for controlling acute vomiting. "
02/01/2003 - "The introduction of serotonin 5-HT(3)-receptor antagonists into clinical practice allowed for a dramatic improvement in the management of vomiting. "
11/14/2014 - "This study was the first to determine the relationship between 5-HT and emesis-induced motor activity."

05/01/1981 - "The results showed that the dose of droperidol used in this study was very effective in reducing vomiting in children 11 to 15 years of age. "
05/01/1995 - "There was a significant reduction in the incidence of vomiting in the recovery room (1.4% vs 9.2%, P < 0.005) and in the day ward (9.4% vs 18.3%, P < 0.05) in patients receiving droperidol. "
01/01/1992 - "Droperidol seems to be more effective in reducing severe vomiting. "
01/01/1992 - "Droperidol was more effective in reducing severe vomiting. "
01/01/2012 - "In 128 patients (89%) rescue therapy with a median dose of 10.9 µg/kgBW droperidol was effective but vomiting persisted in 16 patients (11%). "

07/01/2014 - "In conclusion, palonosetron and first-generation 5-HT3 RAs were at least equally effective in emesis prophylaxis for allo-HSCT recipients. "
08/01/2014 - "However, palonosetron has also shown consistent improvement in the suppression of delayed emesis. "
02/01/2016 - "Patients' satisfaction, assessed using Functional Living Index-Emesis (FLI-E), GTDS cycle were higher than those of palonosetron cycle in GP group (FLI-E score; median 1549.5 in GTDS cycle, median 1670.0 in palonosetron cycle). "
08/01/2014 - "Results provide a possible explanation for palonosetron's enhancement of the inhibition of the SP response and suggest that the effect of palonosetron and NK1 receptor antagonists on prevention of delayed emesis could be additive. "
07/01/2014 - "Patients receiving palonosetron, especially for acute emesis, required rescue therapy less frequently than those receiving first-generation 5-HT3 RAs. "

05/01/2010 - "The proposed antiemetic protocol is effective for controlling vomiting in chemotherapy regimens with an HL of 1-3. For highly emetogenic regimens, the antiemetic protocol is also effective, but protection is not complete. "
05/01/2004 - "These drugs have dramatically improved prophylaxis of chemotherapy-induced emesis, particularly when used in combination with a corticosteroid. "
11/01/1995 - "The combination of PNC + DXM is more efficacious than PNC + PLC in protection against highly emetogenic chemotherapy-induced vomiting."
11/01/1993 - "In fact, 70-80% of patients submitted to highly or moderately emetogenic drugs achieve complete protection against vomiting during the first cycle of chemotherapy. "
03/01/1997 - "The three drug combination significantly improved complete control of acute and delayed emesis over successive chemotherapy cycles."

07/01/2006 - "Acupressure (two trials) and acupuncture (six trials) modalities were effective in reducing vomiting (P < .005); however, ETS (two trials) did not show significant effects in reducing the vomiting (P = .118) in children. "
07/01/2004 - "This study suggests that acupressure on P6 point appears to be an effective adjunct maneuver in the course of emesis control."
05/01/2006 - "Korean hand acupressure stimulations (two trials) had the best impact on reducing vomiting. "
07/01/2012 - "The overall incidence of vomiting from 0 to 72 hours after surgery was also significantly decreased from 30% to 12% in the acupressure group (P = 0.03, 95% confidence interval 2%-33%). "
07/01/2012 - "The incidence of vomiting at 24 hours was significantly decreased in the acupressure group (10% vs 26%, P = 0.04, 95% confidence interval for absolute risk reduction 1%-31%). "

01/01/2015 - "A visual analog scale was used to evaluate analgesia and the degree of malignant vomiting. "
09/01/2014 - "Vomiting is a common complication associated with the use of hydromorphine for pre-emptive analgesia in dogs. "
02/01/2014 - "This clinical policy from the American College of Emergency Physicians is the revision of a 2005 clinical policy evaluating critical questions related to procedural sedation in the emergency department.1 A writing subcommittee reviewed the literature to derive evidence-based recommendations to help clinicians answer the following critical questions: (1) In patients undergoing procedural sedation and analgesia in the emergency department,does preprocedural fasting demonstrate a reduction in the risk of emesis or aspiration? "
01/01/2014 - "The computer-based predictive model should be useful in increasing vigilance in those patients most at risk for vomiting while PCEA is used, allowing for patient-specific therapeutic intervention, or even in suggesting the use of alternative methods of analgesia. "
06/01/2010 - "Cannabis has been used recreationally for its psychotropic properties, while effects such as stimulation of appetite, analgesia and anti-emesis have lead to the medicinal application of cannabis. "

01/01/2010 - "A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres."
11/01/1998 - "International study results concerning radiotherapy-induced emesis are demonstrated. "
05/01/2012 - "The patients documented emesis daily during the radiotherapy period. "
06/01/2011 - "Pilot testing of methods for evaluation of acupuncture for emesis during radiotherapy: a randomised single subject experimental design."
01/01/2009 - "Twenty patients(95%)completed chemoradiotherapy, although one patient quit radiotherapy due to vomiting. "

04/01/2008 - "A significant reduction in paediatric post-tonsillectomy vomiting through audit."
01/01/2011 - "Routine use in five children would be expected to result in one less patient experiencing post-tonsillectomy emesis (risk difference (RD) -0.24; 95% CI -0.32 to -0.15; P < 0.00001). "
01/01/2009 - "Current management of vomiting after tonsillectomy in children."
04/01/2008 - "At-home use of ODT may prevent emesis in children during the first 3 days after tonsillectomy in children. "
06/01/2005 - "Application of TEAS on sedated children is an easy, painless, reliable and effective method for the prophylaxis of postoperative retching and vomiting in pediatric tonsillectomy."